跳至主要内容
临床试验/ISRCTN62033854
ISRCTN62033854已完成未知

Magnetic resonance imaging to characterise invasive phenotypes in cerebral gliomas: an observational prospective cohort study

Cambridge University Hospitals NHS Foundation Trust (UK)0 个研究点目标入组 145 人开始时间: 2011年3月4日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
145

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Imaging appearances of a high grade glioma
  • 2. Likely to be suitable for radiotherapy (60 Gy) with concomitant and adjuvant temozolomide
  • 3. World Health Organization (WHO) performance status (PS) grade 0 or 2
  • 4. Aged 18 - 75 years, either sex
  • 5. Resection or biopsy (although only those suitable for maximal resection will be considered for the MALTING Trial)
  • Patients for the MALTING Trial will be felt by their consultant neurosurgeon to be suitable for 5-aminolevulinic acid (5-ALA) fluorescence-guided resection with insertion of carmustine wafers.

排除标准

  • 1. Unsuitable for a contrast-enhanced MRI (MR unsafe metallic implants, claustrophobia, allergy to gadolinium contrast agent or severe renal impairment)
  • 2. Pregnant
  • 3. Allergic to aminolevulinic acid
  • 4. Suffering from porphyria. Care will be taken if the patient is taking other photosensitising drugs.

研究者

相似试验

Markers of Aggressive Local Therapy In Newly... | 临床试验